Universal Beteiligungs und Servicegesellschaft mbH Has $6.10 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN

Universal Beteiligungs und Servicegesellschaft mbH trimmed its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 21.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 302,804 shares of the company’s stock after selling 84,412 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.06% of Elanco Animal Health worth $6,098,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Primecap Management Co. CA increased its position in Elanco Animal Health by 3.1% in the 2nd quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock valued at $739,230,000 after acquiring an additional 1,543,279 shares in the last quarter. Brandes Investment Partners LP grew its stake in shares of Elanco Animal Health by 11.3% during the second quarter. Brandes Investment Partners LP now owns 8,100,322 shares of the company’s stock valued at $115,673,000 after purchasing an additional 820,901 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Elanco Animal Health by 104.5% in the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after purchasing an additional 2,445,872 shares in the last quarter. Jennison Associates LLC raised its position in Elanco Animal Health by 322.0% in the 2nd quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock worth $46,192,000 after purchasing an additional 2,468,122 shares during the last quarter. Finally, Holocene Advisors LP raised its position in Elanco Animal Health by 29.1% in the 2nd quarter. Holocene Advisors LP now owns 2,886,294 shares of the company’s stock worth $41,216,000 after purchasing an additional 649,820 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Insider Activity

In other news, Director Lawrence Erik Kurzius bought 10,000 shares of the business’s stock in a transaction on Friday, December 12th. The shares were bought at an average cost of $21.30 per share, for a total transaction of $213,000.00. Following the completion of the acquisition, the director owned 131,773 shares in the company, valued at approximately $2,806,764.90. This trade represents a 8.21% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeffrey N. Simmons purchased 22,000 shares of Elanco Animal Health stock in a transaction dated Thursday, December 11th. The shares were purchased at an average cost of $21.75 per share, for a total transaction of $478,500.00. Following the completion of the transaction, the chief executive officer owned 167,000 shares of the company’s stock, valued at approximately $3,632,250. This represents a 15.17% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 43,450 shares of company stock worth $937,883 over the last three months. Company insiders own 0.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on ELAN shares. JPMorgan Chase & Co. upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $18.00 to $24.00 in a research report on Tuesday, October 7th. Argus upgraded Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a report on Wednesday, November 19th. KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, December 10th. UBS Group upped their target price on shares of Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Finally, Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 19th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $25.11.

Elanco Animal Health Trading Up 1.3%

NYSE:ELAN opened at $24.71 on Tuesday. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $25.29. The firm has a market capitalization of $12.28 billion, a price-to-earnings ratio of 411.90, a PEG ratio of 3.39 and a beta of 1.87. The business’s 50-day moving average price is $22.81 and its two-hundred day moving average price is $20.12.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, equities analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.